Chemomab Therapeutics (CMMB) Return on Capital Employed (2019 - 2025)
Chemomab Therapeutics posted quarterly Return on Capital Employed of 308.65% for Q4 2025, down 22177.0% year-on-year from N/an in Q4 2024, and down 106.58% on a QoQ basis from 149.41% in Q3 2025.
Chemomab Therapeutics (CMMB) has 6 years of Return on Capital Employed data on file, last reported at 308.65% in Q4 2025.
- For the quarter ending Q4 2025, Return on Capital Employed fell 22177.0% year-over-year to 308.65%; the trailing twelve-month figure through Dec 2025 stood at 308.65% (down 22177.0% YoY), and the FY2025 full-year result was 68.78%, up 2143.0% from the prior year.
- Return on Capital Employed for Q4 2025 stood at 308.65%, down from 149.41% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 139.82% in Q3 2023 and bottomed at 308.65% in Q4 2025.
- The 5-year median for Return on Capital Employed is 10.28% (2022), against an average of 16.32%.
- The widest annual swing landed in 2023, when Return on Capital Employed soared 14218 bps; it then tumbled 25794 bps in 2025.
- A 5-year view of Return on Capital Employed shows it stood at 31.59% in 2021, then soared by 242 bps to 44.71% in 2022, then soared by 201 bps to 134.48% in 2023, then plunged by 165 bps to 86.88% in 2024, then tumbled by 255 bps to 308.65% in 2025.
- The last three Return on Capital Employed figures came in at 308.65% (Q4 2025), 149.41% (Q3 2025), and 86.88% (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | Chemomab Therapeutics | 959.23 Mn | 948.86 Mn | - | -308.65% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -308.65% |
| Sep 30, 2025 | -149.41% |
| Dec 31, 2024 | -86.88% |
| Sep 30, 2024 | 108.53% |
| Jun 30, 2024 | 122.88% |
| Mar 31, 2024 | 122.01% |
| Dec 31, 2023 | 134.48% |
| Sep 30, 2023 | 139.82% |
| Jun 30, 2023 | 131.32% |
| Mar 31, 2023 | 99.83% |
| Dec 31, 2022 | 44.71% |
| Sep 30, 2022 | 10.28% |
| Jun 30, 2022 | -10.86% |
| Mar 31, 2022 | -26.85% |
| Dec 31, 2021 | -31.59% |
| Sep 30, 2021 | -16.40% |
| Jun 30, 2021 | -5.76% |
| Dec 31, 2019 | 21.57% |
| Sep 30, 2019 | 107.07% |
| Jun 30, 2019 | 50.06% |
| Mar 31, 2019 | 75.31% |